Cardiovascular prevention is entering a more personalized era as cardiologists recognize that focusing solely on LDL cholesterol leaves significant gaps in risk assessment. The persistence of heart attacks and strokes even among patients achieving LDL targets has driven clinicians to examine overlooked lipid factors that contribute to what researchers term 'residual cardiovascular risk.' The 2025 European guidelines now formally incorporate lipoprotein(a) and C-reactive protein as risk modifiers that should influence treatment decisions, particularly in younger adults where traditional risk calculators often underestimate danger. This represents a meaningful shift from the one-size-fits-all LDL approach toward stratified medicine based on individual risk profiles. The guidelines also endorse aggressive early combination therapy immediately following acute coronary events, rather than the traditional stepwise escalation that may leave patients vulnerable during the highest-risk period. Beyond statins, clinicians now have an expanding arsenal including ezetimibe, bempedoic acid, and PCSK9 inhibitors, with novel therapies in late-stage development promising even more targeted interventions. This evolution reflects growing recognition that atherosclerosis involves multiple pathways beyond cholesterol metabolism, including inflammation and genetic predisposition. While the fundamental importance of lifestyle modification remains unchanged, these guidelines acknowledge that many patients require pharmaceutical intervention to achieve meaningful risk reduction. The challenge lies in translating these sophisticated risk assessment tools into routine clinical practice, where time constraints and complexity often favor simpler approaches despite potentially suboptimal outcomes.